Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabipur 1-Year Persistence in Chinese Children
NCT03192371Phase 4Withdrawn
- Sponsor
- GSK
- Start
- Feb 2018
- Primary completion
- May 2019
- Modality
- Whole Inactivated Vaccines
01
Overview
Phase 4, randomised, open-label trial of Human Diploid Cell Rabies Vaccine in rabies (2 arms), sponsored by GSK. Primary endpoints: Evaluation of immunogenicity in terms of antibody concentrations at Day 393, Percentage of subjects with RVNA concentrations ≥ 0.5 IU/mL at Day 393 and 1 more. Planned start Feb 2018; status: withdrawn.
02
Drugs
Human Diploid Cell Rabies Vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on NCT03192371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192371.